Topic: artificial intelligence
Pharma customer service reps can’t just Google the answers to doctor questions about their company's drugs. But now, at Biogen, they can.
BeiGene rebuffs claims that it inflated drug sales records; Sumitomo Dainippon pays $3 billion upfront for five "vants"; Genentech settles with JHL Biotech.
Biocon's manufacturing problems cost it and Mylan again; CStone's CEO racks up nearly $20 million in 2018 pay; Novartis sells Suzhou plant.
Sun's Shanghvi took a 99% pay cut last year. Dr. Reddy's copies of Copaxone and NuvaRing were rejected by the FDA. Natco eyes China amid hardship.
Consultancy ZS recently launched an editorial series called "AI &" to dive into artificial intelligence best practices for pharma.
Join this webinar to learn the five characteristics of a unified platform and how each benefits clinical research both for a single trial and across your suite of research efforts.
A new, promising data source that could help explore and unlock new discoveries lies in the use of simulated data that can be used in place of real patient information.
Pharma has drawn flak in the past for its digital lag, but there's good reason to proceed with caution where AI is concerned, one expert says.
From smart insulin pen caps to artificial intelligence systems for seniors, Novo Nordisk capped its first innovation challenge last month.
Chief digital officers in pharma are here to stay as they transform business and marketing practices.